When
Monday December 7, 2015 at 9:00 AM EST -to- Tuesday December 8, 2015 at 5:00 PM EST
Add to Calendar
Where
FHI360 Conference Center
1825 Connecticut Avenue NW
Washington, DC 20009
Driving Directions
|
|
Key Information
What:
FCAA 2015 AIDS Philanthropy Summit
When:
December 7th
9:00 am - 7:00 pm (including a reception)
December 8th
9:00 am - 5:00 pm
Where:
FHI 360 Conference Center, 1825 Connecticut Avenue, NW, Washington, DC 20009
How (do I get involved?):
- Download the Summit Brief & Agenda- Register today!
|
|
|
|
FCAA invites you to join us on
December 7th & 8th for the
2015 AIDS Philanthropy Summit
Restoring Urgency, Renewing Commitments
Last week we highlighted our two terrific "Advancing Justice" sessions organized by the Open Society Foundations and Alliance for Justice.
Today we turn the spotlight on our "Access to Treatment" concurrent sessions. Both sessions focus on the critical role of civil society and community-based organizations in critical research and advocacy efforts to ensure improved access to, and retention in, care. In the interim, we encourage you to register early (early bird registration ends October 23rd) and to encourage your staff, colleagues and partners to attend.
We look forward to seeing you in D.C.!
Best Regards,
 |
|
_________________________________________________
ACCESS TO TREATMENT: INTERNATIONAL SESSION
Monday 7 December
2:15 - 3:30 pm
Designed by: International Preparedness Coalition
Investing in Communities: Linking Demand with Intellectual Property Literacy and Advocacy for Sustained HIV Treatment Access
The history of the HIV movement has shown that generic competition is the most effective way to reach affordable prices of HIV treatment. The cost of a first-line antiretroviral (ARV) regimen dropped from US$10,000 to less than US$100 per person per year due to the absence of legal and intellectual property (IP) barriers in the early 2000's and in some cases to the effective use the Trade-Related Aspects of Intellectual Property Rights (TRIPS) flexibilities, such as patent oppositions and compulsory licenses. Civil society's role has been instrumental in establishing and sustaining treatment demand by catalyzing national treatment programs, determining priority medicines, and systematically addressing market barriers to sustainable HIV treatment access.
In the post-TRIPS era, IP protections on medicines are implemented in the majority of developing countries. Patents are now granted on recently developed ARVs, including in India, and price decreases previously observed for first-line ARVs is unlikely to happen automatically. In addition, the majority of second- and third-line ARVs remain expensive and out of reach in many countries and where such drugs are available, their sheer cost contribute such heavy burden on national treatment budgets.
This panel discussion organized by ITPC, in presence of key activists at the forefront of the fight for access to medicines in developing countries, seeks to highlight the changes in the intellectual property framework globally and in Low and Middle income-countries, and explore the role of funders in supporting civil society work on intellectual property and access to medicines.
Moderator: Nadia Rafif (MSM-GF, USA)
Panelists: Othoman Mellouk (ITPC, Morocco), Sergiy Kondratyuk (All Ukranian Network of People living with HIV, Ukraine), Alma De Leon (ITPC-LATCA, Guatemala)
Recommended Tweet:
@ITPCglobal session at #FCAASummit on critical need to support civil society on IP & access2med issues Register today bit.ly/1Oioa4t
|
|
_________________________________________________
ACCESS TO TREATMENT: DOMESTIC SESSION
Monday 7 December
2:15 - 3:30 pm
Designed by: Kaiser Permanente
Community-Based HIV Research: Blessed or Doomed?
Community-based organizations (CBO) can help reach socially vulnerable HIV-positive people to support acquisition of HIV medical care in ways health care providers are not able to. CBO interventions show some promise in improving HIV care acquisition, and CBOs can participate in more rigorous evaluations to assess impact of their programs.
To address the health concerns of populations disproportionately at risk for HIV, seven organizations, including the North Jersey Community Research Initiative (NJCRI) and Kaiser Permanente (KP), have joined forces in an effort to link people living with HIV (PLWH) to clinical care through the $2.75 million Kaiser Permanente Community-Based HIV Test and Treat Initiative. Seven community-based agencies across the country were funded to implement and evaluate innovate interventions to increase linkage to and retention in HIV care. While there is clear clinical evidence on linking patients to and retaining patients in care, KP wanted to test those interventions in a community setting, particularly with vulnerable, minority populations.
The preliminary findings are promising. However one of the greatest challenges to the success of this initiative has been the research nature of its rigorous cross-site evaluation. The objective of the evaluation is to assess impact of community-based HIV linkage to care programs using two armed controlled trial designs at each site. The Institutional Review Board (IRB) is a requirement for Kaiser Permanente and for any research conducted on human subjects. IRB lends credibility to research conducted with human subjects and will allow KP to use the findings from your work to inform the broader field. While it lends credibility to the work and allows KP to share the learnings with the broader field, IRB can pose challenges to community organizations due to bureaucratic inflexibility.
This session will take a deep dive into these issues and provide a forum for discussion and collaboration.
Moderator: John Edmiston (Kaiser Permanente)
Panelists: Alexandra Caraballo (Kaiser Permanente), Cory De Stefano (North Jersey Community Research Initiative).
Recommended Tweet:
@KPShares session at #FCAASummit on opportunities & challenges in funding community-based #HIV research Register now bit.ly/1Oioa4t
|
|
|
Registration
Registration is limited to private and public funders, philanthropic infrastructure groups, and invited presenters/guests. The registration fees below cover admission to the Summit, breakfast and lunch on both days and a reception. Hotel accommodation is not included. Fees will be:
|
| Early Bird
(Before Oct. 23rd) | Regular
(After October 24th) | | Member | $150 | $250 | | Non-Member | $250 | $350 |
In order to utilize the Member Rate, your institution must be a 2015 member organization of FCAA, OR a representative of an affinity group. For more information, please visit FCAA's Membership page or contact Sarah Hamilton at [email protected].
Refund Policy
FCAA will refund your registration fees at the following amounts:
- 100% if you cancel before Friday, November 20, 2015
We regret that we will not be able to provide any refunds after Friday, November 20, 2015. If you would like to transfer your registration to another colleague, please contact [email protected].
FCAA did NOT block any hotel rooms for this conference. For those interested, FHI360 has developed a list of suggested accommodations near the conference venue.
|
|
|
FIVE REASONS TO ATTEND:
-
An agenda featuring 12 member-designed sessions focused on: access to treatment, advancing justice, reaching MSM/transgender populations, and retooling the response through new approaches and partners, among others.
-
Plenary sessions will tackle the current landscape of private funding for HIV/AIDS, the intersection of politics and HIV funding, and finally, the increasing urgency around HIV programming for adolescents.
- The exclusive launch of FCAA's annual resource tracking report - Philanthropic Support to Address HIV/AIDS in 2014
- New opportunities to address and engage with a potential audience of US and European funders responsible for disbursing $592 million in support of global HIV/AIDS efforts in 2013.
- Three deep-dive opening sessions sponsored by current FCAA funder working groups on: HIV in the U.S. South; the intersection of HIV and human rights; and, women & children. Each of these sessions will feature a 90-minute funder discussion (open to all), and a 90-minute panel presentation.
|
|
|
